Abstract
Post stroke depression or PSD is believed to occur in ten to forty percent of all patients who survive stroke. These mood disturbances overlap with primary major depressive disorder in terms of symptom profile, natural history and response to antidepressant medications. Cognitive changes, especially impairments in executive functions, are commonly encountered in PSD. This may be the result of disruption to fronto-thalamo-cortical circuits in PSD. Both functional limitations following stroke and biological mechanisms may play important roles in the pathophysiology of PSD. Antidepressants are clinically effective in managing these mood disturbances and may have an important role in the prophylaxis of depression following stroke. PSD provides a naturalistic model that facilitates the study of the clinical correlates and neurobiological mechanisms that may be relevant in the pathophysiology of vascular depression.
Keywords: stroke, depression, location, executive dysfunction, norepinephrine, serotonin, antidepressants, prophylaxis
Current Neuropharmacology
Title: The Clinical Neuroscience of Post Stroke Depression
Volume: 2 Issue: 4
Author(s): Ebrahim Haroon and Anand Kumar
Affiliation:
Keywords: stroke, depression, location, executive dysfunction, norepinephrine, serotonin, antidepressants, prophylaxis
Abstract: Post stroke depression or PSD is believed to occur in ten to forty percent of all patients who survive stroke. These mood disturbances overlap with primary major depressive disorder in terms of symptom profile, natural history and response to antidepressant medications. Cognitive changes, especially impairments in executive functions, are commonly encountered in PSD. This may be the result of disruption to fronto-thalamo-cortical circuits in PSD. Both functional limitations following stroke and biological mechanisms may play important roles in the pathophysiology of PSD. Antidepressants are clinically effective in managing these mood disturbances and may have an important role in the prophylaxis of depression following stroke. PSD provides a naturalistic model that facilitates the study of the clinical correlates and neurobiological mechanisms that may be relevant in the pathophysiology of vascular depression.
Export Options
About this article
Cite this article as:
Haroon Ebrahim and Kumar Anand, The Clinical Neuroscience of Post Stroke Depression, Current Neuropharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570159043359567
DOI https://dx.doi.org/10.2174/1570159043359567 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Inspired Nitric Oxide and Modulation of Oxidative Stress During Cardiac Surgery
Current Drug Safety Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans
Current Protein & Peptide Science The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Physiological Significance of Resistin and Resistin-Like Molecules in the Inflammatory Process and Insulin Resistance
Current Diabetes Reviews Bleeding and Acute Coronary Syndromes: Defining, Predicting, and Managing Risk and Outcomes
Current Drug Targets Endoplasmic Stress Inhibitors for Homocysteine Induced Cardiovascular Disease
Current Pharmaceutical Design Characterizing Blood Pressure, Heart Rate, Physical Activity, Circadian Rhythm and their Response to NOS Inhibitor and Substrate in CHF Rats with Telemetry
Vascular Disease Prevention (Discontinued) Five Markers Capable to Identify Passive Smoking Exposure Associated with Endothelial Dysfunction in Healthy Individuals
Current Hypertension Reviews GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Current Pharmaceutical Design Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues
Current Drug Safety Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design Glucocorticoids in Pregnancy
Current Pharmaceutical Biotechnology Insight into Molecular and Functional Diversity of Tachykinins and their Receptors
Protein & Peptide Letters Association Between the Levels of Circulating Adhesion Molecules and Biopterins in Type-2 Diabetic Normotensive Patients Adhesion Molecules and Biopterins
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews